Pipeline
We continue to push the boundaries of scientific innovation by leveraging our RNA sequencing and machine learning capabilities to expand our current offerings and – eventually – enable earlier disease detection. Key product-development initiatives include:

Xpression AtlasIn May 2018, we launched our Afirma Xpression Atlas, providing physicians with significant amounts of rich genomic content – gene expression, DNA variants and RNA fusion data – on clinical samples to inform surgery and treatment options for patients with suspected thyroid cancer. This innovation also enabled our research collaboration with Loxo Oncology, which is intended to support their development of targeted therapies for genetically defined cancers, including thyroid cancer. We believe our Xpression Atlas platform can also be transferred to our pulmonology indications and are in the early stages of pursuing such opportunities to further improve patient care and advance precision medicine in lung cancer and idiopathic pulmonary fibrosis.

Leveraging “Field of Injury” Technology to Enable Early Lung Cancer Diagnosis We are currently exploring opportunities to utilize the same “field of injury” technology that powers our Percepta classifier to develop a nasal swab test that can enable earlier lung cancer detection – and ultimately help reduce lung cancer deaths. Our scientists plan to collaborate with preeminent pulmonology thought leaders to build on compelling findings published in 2017 in the 
Journal of the National Cancer Institute in which Boston University researchers showed that the molecular changes that enable lung cancer to be detected in the main lung airway with Percepta can also be detected in the nose.

Pipeline